caa a22 4500 469026421 CHVBK 20180323132731.0 cr unu---uuuuu 170328e19920801xx s 000 0 eng 10.1007/BF01962548 doi (NATIONALLICENCE)springer-10.1007/BF01962548 Beijnen J. Slotervaart Hospital/Netherlands Cancer Institute, Louwesweg 6, 1066, EC Amsterdam, the Netherlands aut New cytotoxic drugs and targets in oncology [Elektronische Daten] [J. Beijnen] New agents in the preclinical and early clinical pipeline (phases I and II) are described and some of the problems associated with their development are reviewed. The article focuses on tubulin poisons such as taxol, topoisomerase inhibitors, such as topotecan, and drugs such as bryostatin 1 and miltefosin, which interfere with specific signal transduction pathways involved in malignant cell growth. Royal Dutch Association for Advancement of Pharmacy, 1992 Bryostatin 1 nationallicence New cytotoxic drugs nationallicence Signal transduction nationallicence Taxol nationallicence Topoisomerase inhibitors nationallicence Topotecan nationallicence Tubulin poisons nationallicence Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 258-267 0031-6911 14:4<258 1992 14 11096 https://doi.org/10.1007/BF01962548 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01962548 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Beijnen J. Slotervaart Hospital/Netherlands Cancer Institute, Louwesweg 6, 1066, EC Amsterdam, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 258-267 0031-6911 14:4<258 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer